医学
肝损伤
怀孕
药品
产后
产科
内科学
药理学
遗传学
生物
作者
Umair Masood,Nicholas Venturini,Paola Nicoletti,Andrew Dellinger,David E. Kleiner,Herbert L. Bonkovsky,Huiman X. Barnhart,Raj Vuppalanchi,Simona Rossi,Joseph A. Odin,Tatyana Kushner
标识
DOI:10.1097/aog.0000000000005585
摘要
There are limited data on the causative agents and characteristics of drug-induced liver injury in pregnant individuals. Data from patients with drug-induced liver injury enrolled in the ongoing multicenter Drug-Induced Liver Injury Network between 2004 and 2022 and occurring during pregnancy or 6 months postpartum were reviewed and compared with cases of drug-induced liver injury in nonpregnant women of childbearing age. Among 325 individuals of childbearing age in the Drug-Induced Liver Injury Network, 16 cases of drug-induced liver injury (5%) occurred during pregnancy or postpartum. Compared with drug-induced liver injury in nonpregnant women, pregnancy-related drug-induced liver injury was more severe ( P <.05). One elective termination and three miscarriages were documented; there were no maternal deaths. We recommend that isoniazid for latent tuberculosis be deferred to the postpartum period whenever feasible and that β-blockers or calcium channel blockers rather than methyldopa be used for hypertension management during pregnancy.
科研通智能强力驱动
Strongly Powered by AbleSci AI